71
Participants
Start Date
February 15, 2015
Primary Completion Date
July 20, 2020
Study Completion Date
September 8, 2020
Benfotiamine
"* To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
Burke, White Plains
Lead Sponsor
Burke Rehabilitation Hospital
OTHER
Columbia University
OTHER
National Institute on Aging (NIA)
NIH
Alzheimer's Drug Discovery Foundation
OTHER
Montefiore Medical Center
OTHER
Burke Medical Research Institute
OTHER